Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Nov 01, 2016 Theratechnologies Announces Update from its Healthcare Analyst Day Meeting Oct 28, 2016 Results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-Breaker Session at IDWeek 2016 Oct 24, 2016 Theratechnologies Announces End of Patient Treatment for Phase III Ibalizumab Trial Oct 04, 2016 Theratechnologies Announces Financial Results for Third Quarter of 2016 Sep 28, 2016 Theratechnologies to Move Forward with Development of new Single Vial Formulation for EGRIFTA® (Tesamorelin for Injection) Sep 01, 2016 Theratechnologies Announces Commercialization Agreement for Tesamorelin in Spain and Portugal Aug 18, 2016 Ibalizumab Phase III Study Primary End-Point Results To Be Presented At IDWEEK 2016 Jul 05, 2016 Theratechnologies Announces Financial Results for Second Quarter of 2016 Jun 28, 2016 Theratechnologies to announce financial results for the second quarter of 2016 Jun 09, 2016 Theratechnologies announces regretful decision by the quebec ministry of health First page « Previous page ‹ … Page 27 Page 28 Page 29 Page 30 Current page 31 Page 32 Page 33 Page 34 Page 35 … Next page › Last page » Displaying 301 - 310 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Oct 28, 2016 Results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-Breaker Session at IDWeek 2016
Sep 28, 2016 Theratechnologies to Move Forward with Development of new Single Vial Formulation for EGRIFTA® (Tesamorelin for Injection)
Sep 01, 2016 Theratechnologies Announces Commercialization Agreement for Tesamorelin in Spain and Portugal
